BiotechTube
ActiTrexx

ActiTrexx

Munich, Germany· Est.
actitrexx.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.3M

Overview

ActiTrexx is a clinical-stage biotech pioneering an allogeneic, activated regulatory T cell (Treg) therapy platform to re-balance the immune system. Its lead candidate, ATreg/Actileucel (ATX-002), is in a Phase Ib/II trial for preventing graft-versus-host disease (GvHD) and represents a 'one product fits all' approach without tissue matching. Founded and led by experts in immunology and cell therapy, the company is supported by German public research grants and focuses on developing potentially curative treatments for severe autoimmune and inflammatory conditions.

Autoimmune DiseasesAutoinflammatory DiseasesTransplant Rejection

Technology Platform

Proprietary platform for ex vivo activation and expansion of allogeneic regulatory T cells (Tregs), designed to create highly suppressive, off-the-shelf cell therapies that do not require tissue matching.

Funding History

2
Total raised:$2.3M
Grant$500K
Seed$1.8M

Opportunities

The large and growing market for autoimmune and inflammatory diseases, with high unmet need for curative therapies, presents a significant opportunity.
The company's 'off-the-shelf' allogeneic platform could offer superior scalability, lower cost, and faster patient access compared to autologous cell therapies, providing a strong competitive advantage if clinically validated.

Risk Factors

Key risks include clinical trial failure of its lead candidate, potential immunogenicity or durability issues with allogeneic cells, and intense competition in the Treg therapy space.
Financial risk is high due to reliance on grants, requiring successful future fundraising to advance development.

Competitive Landscape

ActiTrexx competes in the emerging Treg cell therapy space against other biotechs (e.g., Sangamo/Pfizer, GentiBio, Sonoma Biotherapeutics) and large pharma. Its primary differentiation is the focus on an activated, allogeneic, non-HLA-matched product, which aims to solve key manufacturing and accessibility challenges faced by patient-specific autologous approaches.

More companies in Cell & Gene Therapy →More companies in Germany →